A clinical case with Anti-MOG associated demyelinating disease

Relevance. Anti-MOG-associated diseases are a relatively new and poorly studied group of autoimmune demyelinating disorders. Description of clinical cases helps to expand the understanding of the pathology, its diagnosis and treatment. The relevance of the article also lies in the demonstration of diagnostic algorithms, including the use of specific markers (anti-MOG antibodies) and neuroimaging methods (MRI). Despite the growing interest in this pathology, the number of described cases remains limited.
Objective: to study a clinical case with antiMOG-associated demyelinating disease and to identify the relevance of this disease in our time.
Materials and methods: a clinical case provided in the neurological department of the Republican Clinical Hospital No. 1, Izhevsk.
Results. Upon discharge, the following diagnosis was made: "Demyelinating disease of the central nervous system with the phenotype of ZONM (myelitis with complete regression of symptoms against the background of GC therapy), anti-AQP 4(-) (anti-MOG-associated disease) in the form of mild coordination disorders, mild subcortical syndrome, optic neuritis on the right, asthenic-subdepressive syndrome."
Conclusions. Anti-MOG-associated demyelinating disease is relevant at present, positive dynamics are observed during treatment.

1. Averchenkov D.M., Volik A.V., Fomin V.V., and others. Acute multiple encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;21(11):119‑128.Averchenkov D.M., Volik A.V., Fomin and others. Acute disseminated encephalomyelitis.S.S. Korsakov Journal of Neurology and Psychiatry.. 2021;121(11):119-128. ( In Russian.)

2. Belova A.N., Sheiko G.E., Rakhmanova E.M., Boyko A.N. Clinical features and modern diagnostic criteria of the disease associated with antibodies to oligodendrocyte myelin glycoprotein. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2023;123(11):47‑56.

3. Belova A.N., Sheiko G.E., Rakhmanova E.M., Boyko A.N. Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease. S. S. Korsakov, Journal of Neurology and Psychiatry. 2023;123(11):47-56. ( In Russian.)

4. https://doi.org/10.17116/jnevro202312311147

5. Clinical guidelines for diseases of the spectrum of opticopolyneuromyelitis, Republic of Kazakhstan, 2022. Protocol No. 172.4.

6. V. Krasnov. S., Rudneva Yu. A., V. Nazarov. D., Vladykina A.V., Lapin S. V., Zaslavsky L. G., Totolyan N. A. MOGH-IGG-ASSOCIATED DEMYELINATING DISEASE: MODERN CONCEPTS, ISSUES OF DIAGNOSIS AND TREATMENT // PM. 2020. No. 5. URL: https://cyberleninka.ru/article/n/mog-igg-assotsiirovannoe-demieliniziruyuschee-zabolevanie-sovremennye-predstavleniya-voprosy-diagnostiki-i-lecheniya

7. Heftberger R., Guo Y., Flanagan E.P., Lopez-Chiriboga A.S., Endmire V., Hochmeister S., Joldik D., Pittock S., Tillema D.M., Gorman M., Lassman H., Luccinetti K.F. Pathology of the central nervous system is an inflammatory demyelinating disease accompanied by autoantibodies to the glycoprotein of myelin oligodendrocytes. Acta Neuropathol. 2020, May;139(5):875-892. doi: 10.1007/s00401-020-02132- Epub 2020, February 11. PMID: 32048003; PMCID: PMC7181560.